Two allogeneic cell therapy switches in a day
Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.
Adicet pivots
After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.
Affimed looks to reverse a share price collapse
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
KRAS crowding continues
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
Point’s big Splash falls short
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
